Form 4: Bristol-Myers Squibb Executive Benjamin Hickey Reports Stock Transactions
SEC Form 4 Filing
Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 1, 2025, Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reported transactions involving Bristol-Myers Squibb common stock.
- Hickey vested 3,286 restricted stock units, which converted into an equal number of shares of common stock.
- 1,630 shares were withheld for payment of taxes at a price of $59.62 per share.
- Following these transactions, Hickey directly owns 8,789 shares of common stock and indirectly owns 91 shares through a spouse.
- He also directly owns 6,572 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock transactions.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction affects the reporting person's holdings in the company.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of earliest transaction: vesting of restricted stock units and tax withholding. |
| 03/01/2025 | Restricted stock units vest in three equal installments beginning on this date. |
| 03/01/2027 | Expiration date of the restricted stock units. |
| 03/04/2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.